Affluent Medical Valuation
Is AFME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AFME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AFME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AFME's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AFME?
Key metric: As AFME barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is AFME's PB Ratio? | |
|---|---|
| PB Ratio | 2.1x |
| Book | €0 |
| Market Cap | €65.50m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 62.5x |
| Enterprise Value/EBITDA | -5.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does AFME's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.8x | ||
GBT Guerbet | 0.9x | 18.3% | €334.1m |
ALKLH Klea Holding | 2x | n/a | €52.9m |
AMPLI Amplitude Surgical | 1.6x | n/a | €149.7m |
ALCOR Biocorp Production | 62.8x | 136.3% | €154.5m |
AFME Affluent Medical | 2.1x | -33.4% | €65.5m |
Price-To-Book vs Peers: AFME is expensive based on its Price-To-Book Ratio (2.1x) compared to the peer average (1.5x).
Price to Book Ratio vs Industry
How does AFME's PB Ratio compare vs other companies in the FR Medical Equipment Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
ALSPW Spineway | 0.004x | 97.7% | US$80.07k |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Book vs Industry: AFME is good value based on its Price-To-Book Ratio (2.1x) compared to the European Medical Equipment industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is AFME's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate AFME's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.67 | €3.97 +138.2% | 5.2% | €4.20 | €3.70 | n/a | 3 |
| Nov ’25 | €1.88 | €3.97 +111.0% | 5.2% | €4.20 | €3.70 | n/a | 3 |
| Oct ’25 | €1.72 | €3.97 +130.6% | 5.2% | €4.20 | €3.70 | n/a | 3 |
| Sep ’25 | €1.90 | €4.00 +110.5% | 6.1% | €4.30 | €3.70 | n/a | 3 |
| Aug ’25 | €1.98 | €4.00 +102.0% | 6.1% | €4.30 | €3.70 | n/a | 3 |
| Jul ’25 | €1.60 | €3.37 +110.4% | 5.0% | €3.60 | €3.20 | n/a | 3 |
| Jun ’25 | €1.80 | €3.37 +87.0% | 5.0% | €3.60 | €3.20 | n/a | 3 |
| May ’25 | €1.71 | €3.37 +96.9% | 5.0% | €3.60 | €3.20 | n/a | 3 |
| Apr ’25 | €1.75 | €3.40 +94.8% | 5.9% | €3.60 | €3.20 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Equasens Société anonyme
€625.3m
Provides healthcare IT solutions in Europe.
EQS
€41.60
7D
-5.5%
1Y
-26.8%
Laboratoires Euromedis Société anonyme
€13.0m
Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.
ALEMG
€4.57
7D
-4.2%
1Y
-3.8%
emeis Société anonyme
€901.5m
Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
EMEIS
€5.60
7D
-10.5%
1Y
-98.3%